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Background: Non-invasive prenatal testing of trisomy 21 (T21) is being actively investigated using fetal-specific
epigenetic markers (EPs) that are present in maternal plasma. Recently, 12 EPs on chromosome 21 were identified
based on tissue-specific epigenetic characteristics between placenta and blood, and demonstrated excellent clinical
performance in the non-invasive detection of fetal T21. However, the disease-specific epigenetic characteristics of
the EPs have not been established. Therefore, we validated the disease-specific epigenetic characteristics of these
EPs for use in non-invasive detection of fetal T21.
Methods: We performed a high-resolution tiling array analysis of human chromosome 21 using a methyl-CpG
binding domain-based protein (MBD) method with whole blood samples from non-pregnant normal women,
whole blood samples from pregnant normal women, placenta samples of normal fetuses, and placenta samples
of T21 fetuses. Tiling array results were validated by bisulfite direct sequencing and qPCR.
Results: Among 12 EPs, only four EPs were confirmed to be hypermethylated in normal placenta and
hypomethylated in blood. One of these four showed a severe discrepancy in the methylation patterns of T21
placenta samples, and another was located within a region of copy number variations. Thus, two EPs were
confirmed to be potential fetal-specific markers based on their disease-specific epigenetic characteristics. The array
results of these EPs were consisted with the results obtained by bisulfite direct sequencing and qPCR. Moreover,
the two EPs were detected in maternal plasma.
Conclusions: We validated that two EPs have the potential to be fetal-specific EPs which is consistent with their
disease-specific epigenetic characteristics. The findings of this study suggest that disease-specific epigenetic
characteristics should be considered in the development of fetal-specific EPs for non-invasive prenatal testing of T21.
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Prenatal testing is an integral component of modern
obstetric practice and is commonly performed in profes-
sional medical organizations worldwide. The primary aim
of prenatal testing is the diagnosis of fetal aneuploidies,
such as trisomy 21 (T21, Down syndrome), trisomy 18* Correspondence: hmryu@yahoo.com
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stated.(Edwards syndrome) and trisomy 13 (Patau syndrome)
[1]. Although the majority of fetuses with aneuploidy
result in spontaneous termination during fetal develop-
ment, T21 has the highest survival rate, affecting 1 in 800
births [2]. Therefore, prenatal detection of T21 is consid-
ered the most common and important aspect of prenatal
genetic testing. Current prenatal screening tests of T21
have greatly improved by using a combination of maternal
serum markers and fetal sonographic markers such as
nuchal translucency [3-6]. However, positive screening
results require confirmation with diagnostic testing, such
as amniocentesis or chorionic villus sampling (CVS) [7].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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associated with significant risks to the fetus and mother, in-
cluding the potential loss of a healthy fetus [7,8]. For this
reason, invasive prenatal diagnostic tests are currently pre-
formed only in high-risk pregnancies or in pregnancies with
increased maternal age and/or family history of having a
child with an inherited disease. Therefore, developing a
reliable method for non-invasive prenatal testing (NIPT)
for fetal T21 is of critical importance in prenatal care.
To perform NIPT, a source of fetal genetic material
that could be sampled without harm to the fetus is
needed. In 1997, Lo et al. discovered the existence of
cell-free fetal DNA (cff-DNA) in maternal circulation
[9]. It is rapidly cleared from maternal blood within two
hours of delivery and constitutes approximately 10% of
the total DNA in maternal plasma [10,11]. Moreover, it
has recently been found that the entire fetal genome, in
the form of cff-DNA, is present in maternal blood [12].
Therefore, cff-DNA is regarded as a promising new ma-
terial for the development of reliable NIPT of fetal T21.
Various methods have been applied for the NIPT of
fetal T21 using cff-DNA. Recently, the NIPT for T21
based on next-generation sequencing reach sensitivities
and specificities of over 99% and have already been
applied in the clinical setting [13-15]. However, next-
generation sequencing technologies are of high cost and
not easily accessible to diagnostic laboratories, because
requires major and expensive infrastructure. To overcome
these issues, epigenetic modifications as fetal-specific
signatures to detect cff-DNA from circulating maternal
DNA have been investigated. A number of fetal-specific
epigenetic markers (EPs) on chromosome 21 that could
be used for the NIPT of fetal T21 have been reported.
However, the diagnostic accuracy of these fetal-specific
EPs for the NIPT of fetal T21 range from 80 to 100%,
depending on the markers and methods used [16-18].
In a previous study, Papageorgiou et al. identified 12
tissue-specific differentially methylated regions (DMRs)
that are hypermethylated in placental DNA of the euploid
fetus and hypomethylated in non-pregnant female normal
whole blood DNA using methylated DNA immunopre-
cipitation and tiling microarray [19]. The DMRs were
suggested for use as fetal-specific EPs in the NIPT of fetal
T21. They proposed a fetal-specific DNA methylation
ratio method using the EPs for fetal T21 detection and
reported excellent clinical performance (both the sensitiv-
ity and specificity were 100%) [18]. However, the EPs were
selected based on the only tissue-specific epigenetic char-
acteristics between placenta and blood and their disease-
specific epigenetic characteristics have not been validated.
The aim of this study was to validate disease-specific
epigenetic characteristics of EPs for the NIPT of fetal
T21 in whole blood from non-pregnant euploid women,
whole blood from pregnant euploid women, euploid fetalplacenta, and T21 fetal placenta using a high-resolution
tiling array analysis of human chromosome 21 and to
select the effective EPs that have the potential to be used
as fetal-specific EPs for the NIPT of fetal T21.
Methods
Ethics statement
This study was conducted according to the principles
expressed in the Declaration of Helsinki. Appropriate
institutional review board approval for this study was
obtained from the Ethics Committee at Cheil General
Hospital (#CGH-IRB-2011-85). All patients provided
written informed consent for the collection of samples
and subsequent analysis.
Sample processing
Pregnant women with euploid or T21 fetuses and non-
pregnant euploid women who attended the Department of
Obstetrics and Gynecology at Cheil General Hospital,
Korea were recruited between March and December 2011.
Maternal peripheral blood samples were collected into
tubes containing EDTA just before obstetric procedures
(such as CVS) in the first trimester. All placenta samples
were obtained at CVS. Maternal peripheral blood samples
were centrifuged at 1,600 g for 10 min. The peripheral
blood cell portion was re-centrifuged at 2,500 g for 10 min,
and any residual plasma was removed. DNA was extracted
from maternal peripheral blood cells using the QIAamp
Blood kit (Qiagen, West Sussex, UK) and from placental
tissues using the QIAamp Tissue Kit (Qiagen).
Array hybridizations
Whole blood samples from non-pregnant euploid
women, whole blood samples from pregnant euploid
women, euploid fetal placenta samples, and T21 fetal
placenta samples from pregnant euploid women were
used. Each DNA sample was extracted from placental
tissues and maternal blood cells, and then sonicated and
subjected to a methyl-CpG binding domain-based
protein (MBD) method. The subsequent product was
amplified and labeled using a Genomic DNA Enzymatic
Labeling Kit (Agilent Technologies, DE, USA) and
hybridized to a customized chip specific for chromosome
21. The array platforms were composed of 0.4 million
50-mer to 60-mer oligonucleotides covering chromo-
some 21 at a median probe density of 1 per 60 bp.
Microarray protocols, including labeling, hybridization
and post-hybridization washing procedures, were per-
formed as recommended by the manufacturer and are avail-
able at https://www.home.agilent.com. Briefly, the labeled
MBD (Cyanine 5-dUTP: Cy5) DNA and reference DNA
(Cyanine 3-dUTP: Cy3) were cleaned using Amicon filters
(Millipore Corporation, MA, USA). Competitive hybridi-
zation onto the microarray was then performed using a
Table 1 Sequences of primers according to experiment
Experiment Sequences of primers
Bisulfite direct
sequencing
EP6 Forward: 5′-GAT GCG TTA GAT TTA AGG GAG G-3′
Reverse: 5′-CTC ACT CTC ACG AAA CCC CTC-3′
EP7 Forward: 5′-GAG ATG TTT AGC GTT TGT GGG-3′
Reverse: 5′-AAC TAA TTA CAT AAA ACC CAC CC-3′.
qPCR EP6 Forward: 5′-TGA ATC AGT TCA CCG ACA GC-3′
Reverse: 5′-GAA ACA ACC TGG CCA TTC TC-3′
EP7 Forward: 5′-CCG TTA TAT GGA TGC CTT GG-3′
Reverse: 5′-AAA CTG TTG GGC TGA ACT GC-3′
EP9 Forward: 5′-GAC CCA GA CGA TAC CTG GAA-3′
Reverse: 5′- CTG AAC AAA ACT CGG CTT C-3′
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rotating SureHyb chamber at 67°C for 40 h according to
the manufacturer’s instructions. Washed slides were
scanned using a High-Resolution C Scanner (Agilent
Technologies) and fluorescence was evaluated using
Feature Extraction software (Agilent Technologies).
Data analysis of the tiling oligonucleotide arrays
The two signal values were normalized using background
subtraction, and signal ratio (MBD/input), signal log ratio
[log2(MBD/input)], P[X], and P were obtained using Agi-
lent Genomic Workbench software (Agilent Technolo-
gies). The log2 value is the Cy5:Cy3 fluorescence ratio
(methylated DNA recovered by MBD capture: total input
DNA) for each probe, converted to a log2 scale, and repre-
sents a relative measure of the amount of methylated
DNA at each locus. We applied median and Lowess
normalization to the raw data and filtered outlier probes
to remove low-quality data points. The P[X] and P values,
which are used in the MBD array analysis to obtain a
binding call, were defined as the probability that the X
value deviates from the Gaussian distribution of X values
of the entire genome of a sample. Here, the X value for a
probe was the difference between the MBD and the input
signals after adjusting for the symmetry of its distribution.
The value for a probe was calculated as an average X, tak-
ing into account the signals of the neighboring probes
(within 1 kb of the probe). Finally, we defined hyperme-
thylation as a normalized log2 ratio > 0.5, hypomethylation
as a normalized log2 ratio between 0.001 and 0.499, and
unmethylation as a normalized log2 ratio = 0.
Confirmation of copy number variations
The accurate quantification of fetal-specific EPs by
methylation-based DNA discrimination is of critical
importance in the NIPT of fetal T21 using EPs, because
such fetal-specific EPs on chromosome 21 are used in the
detection of fetal T21 by direct comparison with a
placenta-derived DNA methylation marker on a reference
chromosome. Therefore, the fetal-specific EPs should be
selected from regions without copy number variations
(CNVs), which can result in dosage imbalances and inter-
fere with the correct interpretation of results. Therefore,
the DNA sequence of the 12 EPs was checked for the
presence of CNVs or segmental duplication by searching
the Database of Genomic Variants (http://dgv.tcag.ca/dgv/
app/home). The EPs that were free of CNVs and segmen-
tal duplications were selected as fetal-specific EPs with
potential for the NIPT of fetal T21.
Bisulfite direct sequencing
We confirmed the MBD array data using bisulfite direct
sequencing. DNA samples (1 μg) were bisulfite-converted
using an EpiTect Bisulfite Kit (Qiagen) according to themanufacturer’s instructions. The bisulfite-converted DNA
was then amplified by PCR with primers for discrimin-
ation of the methylated and unmethylated CpG sites. The
sequences of PCR primers are presented in Table 1. PCR
reaction solutions contained 10 ng genomic DNA, 10 pM
primers, 0.25 mM dNTPs, 1.5 mM MgCl2, 1 X buffer, and
0.25 U Taq polymerase per 20 μL of total reaction volume.
PCR conditions included predenaturation at 95°C for
10 min, 35 cycles of 95°C for 30 sec, 56°C for 30 sec, 72°C
for 40 sec, and final extension at 72°C for 10 min. After
PCR amplification, PCR products were purified using a
PCR purification kit (Bioneer, Daejeon, Korea) and se-
quenced using a PRISM BigDye Terminator Cycle Sequen-
cing Kit (Applied Biosystems, Foster city, USA) according
to manufacturer’s instructions. Sequencing products were
analyzed using a PRISM 3100 Genetic Analyzer (Applied
Biosystems), and electropherogram traces were interpreted
using Genescan software version 3.7 (Applied Biosystems).
Corresponding genotypes were assigned using Genotyper
software version 3.7 (Applied Biosystems).
Methylation quantification of bisulfite direct sequencing
data
The methylation quantification of bisulfite direct se-
quencing data was performed as described previously
[20]. Briefly, the methylation ratio of each CpG site was
calculated as the peak height of C vs. the peak height of
C plus the peak height of T for each CpG site, as shown
in the computer-generated sequencing chromatogram
extracted from the Chromas program (Version 2.32,
Technelysium). A single C at the corresponding CpG
site was considered to be 100% methylated, a single T
was 100% unmethylated and overlapping C and T was
partially methylated (0-100%).
Noninvasive detection and methylation levels of EPs by
qPCR
We used the PCR conditions described previously [18].
The sequences of PCR primers used are presented in
Table 2 Clinical characteristics of the study population
Characteristics Pregnant women carrying
trisomy 21 fetuses (n = 12)
Pregnant women carrying




Age (years) 32.9 ± 3.5 35.3 ± 4.1 29.5 ± 0.7 0.198a
Body mass index (kg/m2) 21.7 ± 2.5 21.4 ± 2.6 21.1 ± 0.3 0.859a
Gestational age (weeks) 11.8 ± 0.8 12.2 ± 0.6 - 0.182b
Gender-ratio of fetus (male: female) 4:8 14:24 - -
Data are presented as mean ± standard deviation.
aone-way analysis of variance test.
bt-test.
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volume of 20 μL with 20 ng of genomic DNA or 5 μL of
methylated cell free DNA extracted from 1 ml of
maternal plasma. We used SYBR Green PCR master
mix (Eurogentec, Seraing, Belgium). The amplification
program consisted of 3 minutes at 95°C, followed by
40 cycles of denaturation for 15 seconds at 95°C and
annealing/extension for 30 seconds at 62°C. After
amplification, melting curve analysis was performedFigure 1 Methylation levels of EPs in study groups using the tiling ol
expression and non-expression, respectively.by heating the reaction mixture from 65 to 95°C at a
rate of 0.5°C/second.
For analysis of methylation levels of EPs, the delta (Δ)
threshold cycle (Ct) value was calculated as ΔCt = Ctinput -
CtMBD. Input denotes the portion without MBD enrich-
ment and MBD denotes the portion after immunoprecipi-
tation. A positive ΔCt value represents a hypermethylated
region with enrichment, and a negative ΔCt value repre-
sents a hypomethylated region without enrichment.igonucleotide arrays. The red and black colors indicate high
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Data are expressed as a mean ± standard deviation (S.D.).
The clinical data and methylation levels in the study
groups were compared using robust one-way analysis of
variance (ANOVA), the post hoc Tamhane’s T2 test for
multiple comparisons, and the t-test for comparisons be-
tween the two groups. In all tests, a threshold of P < 0.05
was set for statistical significance. Statistical analyses were
performed using the Statistical Package for Social Sciences
12.0 (SPSS Inc., Chicago, USA).
Results
Clinical characteristics
The clinical characteristics of the study groups are
shown in Table 2. In total, whole blood samples from
non-pregnant euploid women (n = 6), whole bloodTable 3 Methylation levels of EPs according to tissue type
EP marker Probe position Placenta (Log2)
(Start-Stop) Trisomy 21 N
EP1 40357972-40358018 0.954 ± 1.087 2.49
40358060-40358114 0.501 ± 0.678 1.66
40358069-40358121 0.513 ± 0.581 1.49
40358132-40358191 0.172 ± 0.173a 0.93
EP2 45336733-45336780 0.756 ± 1.309 1.80
45336822-45336870 0.766 ± 1.327 2.24
45336828-45336876 0.727 ± 1.259 2.15
EP3 45336822-45336870 0.766 ± 1.327 2.24
45336828-45336876 0.727 ± 1.259 2.15
EP4 34398855-34398913 1.650 ± 1.060 b 0.83
34398899-34398948 2.423 ± 1.677 b 1.68
EP5 43316483-43316539 0.775 ± 0.930 2.11
43316494-43316553 0.786 ± 0.972 2.13
43316641-43316700 0.538 ± 0.683 0.97
EP6 43482611-43482655 1.159 ± 1.335 2.88
43482725-43482778 1.624 ± 0.792b,c 2.40
EP7 43484105-43484160 1.505 ± 0.922b,c 1.69
43484227-43484272 0.430 ± 0.656 1.38
EP8 23481701-23481760 0.215 ± 0.372 0.00
EP9 30214808-30214863 0.000 ± 0.000 0.03
EP10 33346983-33347035 1.157 ± 0.930 1.93
33346985-33347037 1.170 ± 1.065 1.95
EP11 45254824-45254879 0.872 ± 0.896 2.00
EP12 38919376-38919423 0.639 ± 1.106 1.76
38919458-38919517 0.814 ± 1.249 1.91
38919529-38919577 0.812 ± 0.948 1.55
Data are presented as mean±standard deviation. Levels were compared using robu
multiple comparisons. In post hoc analysis, statistical significance (P < 0.05) is presen
placenta versus pregnant women blood; cTrisomy 21 placenta versus non pregnant
placenta versus non pregnant women blood.samples and euploid fetal placenta samples from preg-
nant euploid women (n = 38), and whole blood samples
and T21 fetal placenta samples from pregnant euploid
women (n = 12) were used. At blood sampling, age and
body mass index were no differences among all study
groups (P > 0.05 for both). Maternal age, gestational age,
and gender ratio of the fetuses was also not different
between pregnant women carrying T21 fetuses and preg-
nant women carrying normal fetuses (P > 0.05 for all).
Selection of the fetal-specific EPs for the NIPT of fetal T21
In a high-resolution tiling oligonucleotide array of chro-
mosome 21, whole blood samples from non-pregnant
euploid women (n = 2), whole blood samples from preg-
nant euploid women (n = 4), euploid fetal placenta sam-
ples (n = 4), and T21 fetal placenta samples (n = 4) wereNormal blood (Log2) P value
ormal Pregnant Non-pregnant
5 ± 0.662d,e 0.000 ± 0.000 0.037 ± 0.037 0.006
3 ± 0.533d,e 0.000 ± 0.000 0.000 ± 0.000 0.006
6 ± 0.468d,e 0.000 ± 0.000 0.000 ± 0.000 0.005
2 ± 0.282d,e 0.000 ± 0.000 0.000 ± 0.000 0.000
1 ± 1.081 0.000 ± 0.000 0.218 ± 0.218 0.168
7 ± 1.320 0.128 ± 0.221 0.671 ± 0.131 0.143
1 ± 1.257 0.145 ± 0.252 0.892 ± 0.106 0.151
7 ± 1.320 0.263 ± 0.263 0.000 ± 0.000 0.123
1 ± 1.257 0.395 ± 0.421 0.000 ± 0.000 0.145
3 ± 0.547 0.000 ± 0.000 0.000 ± 0.000 0.045
1 ± 1.018 0.000 ± 0.000 0.000 ± 0.000 0.063
6 ± 0.842 0.297 ± 0.515 0.685 ± 0.428 0.072
5 ± 0.914 0.207 ± 0.358 0.470 ± 0.392 0.057
9 ± 1.097 0.446 ± 0.509 0.871 ± 0.029 0.814
7 ± 1.844 0.000 ± 0.000 0.000 ± 0.000 0.070
5 ± 0.651d,e 0.000 ± 0.000 0.000 ± 0.000 0.001
5 ± 0.366d,e 0.000 ± 0.000 0.000 ± 0.000 0.001
4 ± 0.964d 0.000 ± 0.000 0.000 ± 0.000 0.092
0 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.525
6 ± 0.062 0.000 ± 0.000 0.167 ± 0.167 0.165
7 ± 0.338d,e 0.000 ± 0.000 0.000 ± 0.000 0.005
1 ± 0.301d,e 0.000 ± 0.000 0.000 ± 0.000 0.010
2 ± 0.406 0.511 ± 0.642 1.212 ± 0.173 0.088
2 ± 0.963 0.590 ± 0.700 1.393 ± 0.050 0.361
1 ± 0.983 0.471 ± 0.651 1.412 ± 0.073 0.317
6 ± 0.651 0.329 ± 0.570 1.122 ± 0.165 0.256
st one-way analysis of variance (ANOVA), the post hoc Tamhane’s T2 test for
ted as follows: aTrisomy 21 placenta versus normal placenta; bTrisomy 21
women blood; dNormal placenta versus pregnant women blood; eNormal
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and euploid fetal placental samples were paired. The array
data from the 12 EPs in each sample are presented in
Figure 1 and their methylation levels are given in Table 3.
Among the 12 EPs, ten EPs (EP1-EP7 and EP10-EP12)
were identified in probe position of our array and the
other two EPs (EP8 and EP9) were located in regions vary
near the probe position. Among the confirmed 12 EPs,
four EPs (EP2, EP5, EP11, and EP12) were completely
methylated in whole blood samples from non-pregnant
women, whereas two EPs (EP3 and EP4) were completely
unmethylated in one of four euploid placenta samples
(Figure 1). Moreover, these EPs showed various methyla-
tion discrepancies among the T21 placenta samples that
were tested. EP8 and EP9 showed a hypomethylation pat-
tern as a whole, regardless of tissue types and the presence
or absence of disease (Figure 1 and Table 3). Thus, only
four EPs (EP1, EP6, EP7, and EP10) were confirmed to be
hypermethylated in placental samples and hypomethylated
in peripheral blood, regardless of pregnancy status
(Table 3). However, EP1 was completely unmethylated in
two cases among the T21 placenta samples (Figure 1).
Moreover, the methylation levels of EP1 in probe regions
showed significant differences between T21 placenta sam-
ples and normal placenta samples (Table 3).
The CNVs of the 12 EPs is presented in Table 4. Six of
12 EPs (EP2, EP3, EP5, EP8, EP10, and EP11) were
located within chromosomal regions with CNVs. Among
the four EPs (EP1, EP6, EP7, and EP10) showing tissue-
specific epigenetic characteristics between placenta and
blood, EP10 was included within chromosomal regions
with CNVs which can cause incorrect interpretation of
results. Finally, EP6 and EP7 were selected as potentially
fetal-specific EPs for the NIPT of fetal T21.Table 4 Copy number variation of EPs













EP12 37841284-37841411 38919414-38Confirmation of tiling oligonucleotide array data using
bisulfite direct sequencing
We confirmed that the CpG sites of EP6 and EP7 were
hypermethylated in placenta compared with blood using
bisulfite direct sequencing (Figures 2 and 3). Whole
blood samples from non-pregnant euploid women (n = 4),
whole blood samples from pregnant euploid women
(n = 8), euploid fetal placenta samples (n = 6), and T21
fetal placenta samples (n = 5) were used. The CpG
sites of EP6 and EP7 showed a hypermethylated pattern in
placenta compared with blood, regardless of the presence
or absence of disease and pregnancy (Figure 4). The
methylation ratio in each EP6 and EP7 CpG site was
significantly increased in placental samples compared with
blood (P < 0.001 for all CpG sites). However, methylation
ratio between T21 and normal placental samples was not
different (P > 0.05 for all CpG sites).
Confirmation of tiling oligonucleotide array data using
qPCR
We investigated the tissue-specific methylation levels of
EP in whole blood samples from non-pregnant euploid
women (n = 6), whole blood samples from pregnant
euploid women (n = 16), euploid fetal placenta samples
(n = 14), and T21 fetal placenta samples (n = 11) using
qPCR (Table 5). The ΔCt of EP6 and EP7 in whole blood
samples from non-pregnant women and pregnant women
carrying euploid fetuses showed a negative value and pre-
sented a hypomethylated pattern of EPs, whereas the ΔCt
of the EP6 and EP7 in euploid and T21 placenta samples
showed a positive value and presented a hypermethylated
pattern of EPs. The ΔCt of the EP6 and EP7 were signifi-
cantly higher in T21 and euploid placenta samples than in
whole blood samples from pregnant women carryingCopy number variation












Variation_73647 (Loss), Variation_79379 (Gain)
Variation_90815 (Loss), Variation_90816 (Loss)
919541
Figure 2 Bisulfite direct sequencing of EP6. The asterisk represents CpG sites in EP6. Red and blue peaks in sequences indicate T and C bases,
respectively. Red (T) and violet (H) characters represent unmethylated cytosine and heterozygous cytosine, respectively, in CpG sites. CpG sites
of EP6 were completely unmethlylated in normal pregnant blood (A) and were hypermethylated in both normal placenta (B) and trisomy 21
placenta (C).
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all). In addition, we selected EP9 as a negative marker
based on array data and investigated its methylation levels
(Table 5). The ΔCt of EP9 showed a negative value and
presented a hypomethylated pattern in all cases, regardless
of the presence or absence of disease and pregnancy.
There was no statistically significant difference.
Noninvasive detection of selected EPs in maternal plasma
We investigated possibility for noninvasive detection of
selected EPs in maternal plasma using qPCR. The mater-
nal plasma samples from 20 pregnant euploid women
were used. EP6, EP7, and EP9 levels were measured in all
samples without failure of MBD capture. Ct value of EP6,
EP7, and EP9 were 29.4 ± 1.6, 29.5 ± 1.5, and 34.8 ± 4.6,respectively. There was no statistically significant differ-
ence between Ct values of EP6 and EP7 (P = 0.902). How-
ever, Ct value of EP9 was significantly higher than those of
EP6 and EP7 (P < 0.001, Table 5).
Discussion
In this study, we validated that EP6 and EP7 have a
hypermethylated pattern in placenta compared with
blood, regardless of the presence or absence of disease
and pregnancy and are detectable in maternal plasma.
Our results demonstrate that the other ten EPs showed
methylation discrepancies that are opposite previous
microarray data, which were obtained using whole blood
from non-pregnant women and euploid placental sam-
ples or were located in CVN regions which can result in
Figure 3 Bisulfite direct sequencing of EP7. The asterisk represents CpG sites in EP7. Red and blue peaks in sequences indicate T and C bases,
respectively. Red (T) and violet (H) characters represent unmethylated cytosine and heterozygous cytosine, respectively, in CpG sites. CpG sites
of EP7 were completely unmethlylated in normal pregnant blood (A) and were hypermethylated in both normal placenta (B) and trisomy 21
placenta (C).
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EP7 have potential as effective biomarkers for the non-
invasive detection of fetal T21, and that disease-specific
epigenetic characteristic should be considered for devel-
opment of fetal-specific EPs for the NIPT of fetal T21.
In general, 5′-methylcytosine accounts for approxi-
mately 1% of total DNA bases in humans, and therefore
potentially affects 70-80% of all CpG dinucleotides in
the genome [21]. Moreover, DNA methylation patterns
are dynamic and vary during development and across
the genome. DNA methylation has been a topic of
considerable interest in development of biomarkers for
prognosis and diagnosis of various human diseases
including a variety of tumors, Alzheimer’s disease, T21,and others [22-25], because DNA methylation has
disease-specific epigenetic characteristics that vary in the
same tissue according to the presence or absence of
disease. In a previous study investigating the alteration
of DNA methylation depending on T21 disease status,
DNA methylation in total peripheral blood leukocytes
and T-lymphocytes from patients with T21 and normal
controls has been profiled and found gene-specific
abnormalities of CpG methylation in patients with T21
[22]. Therefore, to understand disease-specific epigenetic
characteristics it is important to develop effective EPs
for prognosis and diagnosis of disease.
Recently, the use of epigenetic differences between
maternal whole blood and placental DNA has become
Figure 4 Methylation ratio of each CpG site in EP6 and EP7 by bisulfite direct sequencing. Data are presented as mean ± standard
deviation. Red bars, Trisomy 21 placenta samples (n = 5); orange bars, normal placenta samples (n = 6); yellowish bars, pregnant normal whole
blood (n = 8); green bars, non-pregnant normal whole blood (n = 4). *** P <0.001.
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fetal T21. The quantification of fetal DNA by methyla-
tion-based DNA discrimination has been used for the
NIPT of fetal T21 and promising results have been
reported [16-18]. Such fetal-specific EPs on chromosome
21 are applied for the detection of fetal T21 by direct
comparison with a placenta-derived DNA methylation
marker on a reference chromosome. Theoretically, the
methylation ratio of fetal-specific EPs may present equal
signal intensity for unaffected fetuses and an increased
signal intensity of chromosome 21 for T21 fetuses,
because T21 is caused by an extra copy of all or part of
chromosome 21. To do that, fetal-specific EPs on
chromosome 21 should be hypermethylated in theplacenta and unmethylated in the blood, regardless of
the presence or absence of pregnancy and T21. However,
until now, fetal-specific EPs for the NIPT of fetal T21
have been identified based on the tissue-specific epigen-
etic characteristics between placenta and maternal blood.
The EPs analyzed in this study were also markers identi-
fied by the only tissue-specific epigenetic characteristics
between whole blood from non-pregnant women (n = 5)
and euploid placenta samples (first trimester: n = 3, third
trimester: n = 2) in a previous study [19]. Epigenetic
alteration of these EPs according to the presence or
absence of pregnancy and disease has not been validated.
Nevertheless, the new platform using the methylation
ratio of the EPs has been exhibited excellent clinical
Table 5 Ct values of EPs by qPCR
EP Placenta Blood P value CtMBD of cff-DNA
(n = 20)
P value
Trisomy 21 (n = 11) Normal (n = 14) Pregnant (n = 16) Non-pregnant (n = 6)
EP6
Ctinput 22.3±0.4 23.4±1.5 23.1±2.3 22.3±0.1 0.364 29.4 ±1.6
† 0.021
CtMBD 20.9±0.9
a,b 20.9±1.0c,d 29.3±1.1 29.1±2.3 <0.001
ΔCt 1.5±0.9a,b 2.5±0.9c,d −6.2±2.2 −6.7±2.4 <0.001
EP7
Ctinput 22.8±0.9 24.8±2.5 24.0±2.7 21.8±0.6 0.143 29.5±1.5
#
CtMBD 20.6±0.6
a,b 21.4±0.8c,d 29.3±0.9 27.4±1.7 <0.001
ΔCt 2.2±1.1a,b 3.4±2.2c,d −5.3±2.9 −5.6±1.2 <0.001
EP9
Ctinput 20.7±0.2 21.9±0.6 21.2±0.6 22.9±0.1 0.243 34.8±4.6
CtMBD 28.8±0.6 28.9±1.2 27.0±1.7 28.6±2.0 0.469
ΔCt −8.1±0.4 −7.1±0.8 −5.8±2.1 −5.6±2.1 0.421
Data are presented as mean±standard deviation. Ctinput denotes the threshold cycle of the input portion without methylated DNA enrichment. CtMBD denotes the
threshold cycle of the methylated DNA enriched portion. The delta (Δ) threshold cycle (Ct) value was calculated as ΔCt = Ctinput - CtMBD. The values were compared
using robust one-way analysis of variance (ANOVA), the post hoc Tamhane’s T2 test for multiple comparisons. In post hoc analysis, statistical significance (P < 0.05)
is presented as follows: aTrisomy 21 placenta versus pregnant women blood; bTrisomy 21 placenta versus non pregnant women blood; cNormal placenta versus
pregnant women blood; dNormal placenta versus non pregnant women blood; †EP6 versus EP9; #EP7 versus EP9.
Lim et al. BMC Medical Genomics 2014, 7:1 Page 10 of 11
http://www.biomedcentral.com/1755-8794/7/1performance (both the sensitivity and specificity were
100%) [18,26]. However, Tong et al. reported a low diag-
nostic accuracy (a sensitivity of 33% and a specificity of
73%), in contrast to the perfect classification reported
previously [27]. In this study, we found that most EPs,
except EP6 and EP7, showed discrepant methylation
patterns among the tested samples according to the
presence or absence of pregnancy and T21. Further-
more, only one T21 case seemed methylation pattern
similar to normal cases. This indicates that most EPs iden-
tified in a previous study are likely to lead to inaccurate
results in non-invasive detection of fetal T21. Therefore,
the reproducibility and precision in a realistic clinical
setting of using fetal-specific EPs that do not have disease-
specific epigenetic characteristics is controversial. More
research is needed to confirm utility of fetal-specific EPs
for the NIPT of fetal T21. This study was also limited by
its small sample size and the inclusion of only Korean sub-
jects; therefore, a larger-scale study within different ethnic
populations is needed. Moreover, EPs based on disease-
specific epigenetic characteristics need to be identified for
the NIPT of fetal T21.
Conclusion
In conclusion, we confirmed that EP6 and EP7 had
potential for use as fetal-specific EPs for the NIPT of
fetal T21, due to their consistent disease-specific epigen-
etic characteristics. Therefore, we suggest that consider-
ation of disease-specific epigenetic characteristics of fetal
EPs should certainly take precedence in the development
of effective and reliable EPs for the NIPT of fetal T21.Eventually, the identification of effective fetal-specific
EPs through the consideration of epigenetic characteris-
tics in disease and tissue may reduce the complexity and
cost of these test by excluding the use of inappropriate
biomarkers that produce imprecise results in the NIPT
of fetal T21.
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